The World Health Organization said Friday that two existing treatments dramatically reduced deaths from Ebola and should be given to people of all ages suffering from the often-fatal haemorrhagic disease. Publishing its first-ever guidelines on which therapeutics to use against Ebola, the UN health agency strongly recommended using two monoclonal antibodies, mAb114, also known as Ansuvimab or Ebanga, and REGN-EB3, or Inmazeb. The AFP news agency reports that studies had shown that the two treatments significantly “reduced mortality,” Janet Diaz, lead of the clinical management unit in the WHO’s Health Emergencies programme, told reporters in Geneva.
